Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 367

Results For "ED"

7984 News Found

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
Startup | May 20, 2024

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

The collaboration aims to bolster healthcare entrepreneurship


MMV and GSK win Society of Chemical Industry Innovation Award
News | May 20, 2024

MMV and GSK win Society of Chemical Industry Innovation Award

The award recognizes powerful science–industry collaborations for social good


Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution
Drug Approval | May 18, 2024

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million


Glenmark launches next phase of ‘India First Heart First’ campaign
Healthcare | May 17, 2024

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
News | May 17, 2024

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market

Cresset’s new India site will support the growing demands of Cresset’s APAC customer base


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
News | May 15, 2024

Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr

The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024


Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Diagnostic Center | May 14, 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria